Castle Biosciences, Inc. CSTL
$34.96
$1.524.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.18% | -2.06% | 3.66% | 10.15% | 20.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.18% | -2.06% | 3.66% | 10.15% | 20.40% |
| Cost of Revenue | 23.48% | 19.91% | 17.98% | 22.06% | 26.16% |
| Gross Profit | -1.58% | -6.91% | 0.49% | 7.52% | 19.13% |
| SG&A Expenses | 12.21% | 12.10% | 14.63% | 14.62% | 15.33% |
| Depreciation & Amortization | -46.25% | -48.85% | 32.70% | 85.92% | 85.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.50% | 9.52% | 13.46% | 14.52% | 15.12% |
| Operating Income | -988.41% | -627.31% | -361.94% | -1,329.00% | 81.28% |
| Income Before Tax | -87.40% | -696.03% | -236.87% | -269.82% | -155.09% |
| Income Tax Expenses | 127.14% | -269.20% | -261.37% | -231.92% | 14.92% |
| Earnings from Continuing Operations | -105.10% | -153.15% | -232.41% | -301.42% | -205.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.10% | -153.15% | -232.41% | -301.42% | -205.45% |
| EBIT | -988.41% | -627.31% | -361.94% | -1,329.00% | 81.28% |
| EBITDA | -137.18% | -87.56% | -19.42% | 139.58% | 1,580.23% |
| EPS Basic | -100.37% | -169.24% | -229.22% | -295.43% | -165.63% |
| Normalized Basic EPS | -316.59% | -212.33% | -150.07% | -121.86% | 322.63% |
| EPS Diluted | -82.36% | -118.36% | -239.40% | -326.98% | -161.19% |
| Normalized Diluted EPS | -339.13% | -220.07% | -153.08% | -127.99% | 288.46% |
| Average Basic Shares Outstanding | 4.59% | 4.44% | 4.35% | 4.29% | 4.12% |
| Average Diluted Shares Outstanding | 0.80% | 0.76% | 0.64% | 4.24% | 6.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |